微小残存病変検査の市場規模、シェア＆動向分析レポート：技術別（NGS、PCR）、がんタイプ別（血液悪性腫瘍）、最終用途別（病院）、地域別、セグメント別予測、2023年～2030年

微小残存病変検査市場の成長と動向

Grand View Research, Inc.の新しいレポートによると、世界の微小残存病変検査の市場規模は、2023年から2030年まで11.45%のCAGRで、2030年までに45億米ドルに達すると予測されています。MRD検査が新しい診断・予後判定アッセイとして採用されたことで、あらゆる種類の血液悪性腫瘍を治療するための治療レジームが強固に調整されるようになりました。治療成績の測定は、与えられたがん治療体制をうまく採用するために重要です。

MRDは、がんの状態をよりよく理解し、最終的に治療成果を活用するために重要な分子情報を生み出します。そのため、MRD検査は、腫瘍学に基づく研究のための多数の臨床試験研究においてエンドポイント分析段階としてますます使用され、また、個人の遺伝的特性による治療成果の変動を効果的に記録しています。例えば、2020年11月、Adaptive Biotechnologies Corporationは、GlaxoSmithKline plc.と、GSKの血液治療薬による治療後の残存がん細胞の評価に同社のclonoSEQアッセイを使用する共同研究を開始しました。

他の治療法との併用により腫瘍を外科的に除去しても、がん細胞が完全に除去されるわけではありません。がんの痕跡は体の一部や血流に残っていることがあります。このような残存細胞を診断することは、今後の化学療法や放射線療法の必要性を判断する上で非常に重要です。研究者たちは、MRDを効果的に検出するための非侵襲的な検査を考案しています。例えば、2022年2月、C2i Genomics社の血液検査は、外科的腫瘍治療後の残存がん細胞を定量化しました。また、C2informテストはCEマークのクリアランスを取得し、欧州では「software-as-a-medical-device」MRD検査として提供されています。

がん治療薬は、臨床的なエビデンスに基づいて腫瘍細胞の残留を防ぐために効果的に調節され、また、個人の特定の進行プロファイルに基づいて個別化されます。数多くの調査研究により、効果的な治療のために個人の遺伝的特性を考慮する必要性が高まっています。例えば、2022年10月、Adaptive Biotechnologies Corporationは、血液がんにおけるMRDモニタリングへのアクセスを高めるためにEpicと提携しました。さらに、2021年2月、Natera Inc.は、Personalis Inc.と提携し、治療モニタリング体制とMRDの評価を効果的に設計するために、NeXT腫瘍プロファイリング（Personalis社）と個人向けctDNAプラットフォームSignatera診断製品（Natera社、）の統合による個人向けがん治療の成果を把握することを目的としています。

微小残存病変検査市場のレポートハイライト

MRD検査の高感度と幅広い適用性により、フローサイトメトリーセグメントが2022年の微小残存病変検査市場で圧倒的なシェアを占めた

血液学的悪性腫瘍の有病率の増加により、予測期間中に血液学的悪性腫瘍セグメントが最も速い速度で成長すると予測される

病院や専門クリニックでは、高度な診断機器や熟練した専門家が利用できるため、2022年には病院・専門クリニックセグメントが最も高い収益を上げるセグメントとなる

2022年の微小残存病変検査市場は北米が支配的であり、これは同地域における血液学的悪性腫瘍の有病率の上昇と、整備された償還環境に起因している

目次

第1章 調査手法と範囲

• 市場セグメンテーション
• 調査手法
• 情報調達
  • 購入したデータベース
  • 二次情報
  • 1次調査
  • 1次調査の詳細
• 情報またはデータ分析
  • データ分析モデル
• 市場の策定と検証
• モデルの詳細
  • コモディティフロー分析
    • アプローチ1：コモディティフローアプローチ
    • アプローチ2：ボトムアップアプローチを使用した国別の市場推定
• 世界市場：CAGR計算
• 調査の仮定
• 二次情報のリスト
• 一次情報のリスト
• 目的
• 略語一覧

第2章 エグゼクティブサマリー

• 市場のスナップショット
• セグメントのスナップショット
• 競合情勢のスナップショット

第3章 市場変数、動向、範囲

• 微小残存病変検査市場の系統の見通し
  • 親市場の見通し
    • 細胞健康スクリーニング市場の見通し
    • 体外診断市場の見通し
• 浸透と成長の見通しのマッピング
• 市場促進要因分析
  • がんの有病率の増加
  • MRD検査への投資の増加
  • 調査への投資の増加
• 市場抑制要因分析
  • MRD検査に伴う高コスト
  • MRD検査に関連する複雑な規制の枠組み
• SWOT分析、要因別（政治と法律、経済、技術）
• ポーターのファイブフォース分析
• 規制の枠組み

第4章 微小残存病変検査市場- セグメント分析、技術別、2018年-2030年（100万米ドル）

• 定義と範囲
• 微小残存病変検査市場：技術変動分析
  • フローサイトメトリー
  • ポリメラーゼ連鎖反応（PCR）
  • 次世代シーケンシング（Ngs）
  • その他

第5章 微小残存病変検査市場-セグメント分析、がんの種類別、2018年から2030年（100万米ドル）

• 微小残存病変検査市場：がんタイプの変動分析
  • 血液悪性腫瘍
  • 固形腫瘍

第6章 微小残存病変検査市場-セグメント分析、ビジネス別、2018年から2030年（百万米ドル）

• 定義と範囲
• 微小残存病変検査市場：事業変動分析
  • 病院と専門クリニック
  • 診断検査室
  • 学術調査機関
  • その他

第7章 微小残存病変検査市場-地域ビジネス分析

• 定義と範囲
• 地域市場シェア分析、2022年および2030年
• 地域市場ダッシュボード
• 地域市場のスナップショット
• SWOT分析、要因別（政治と法律、経済と技術）
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • MEA
• 市場規模、予測、トレンド分析、2022年から2030年
• 北米
  • 米国
    • 主要国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
  • カナダ
    • 主要国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
• 欧州
  • 英国
    • 主要国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
  • ドイツ
    • 主要国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
  • スペイン
    • 主要国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
  • フランス
    • 主要国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
  • イタリア
    • 主要国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
  • デンマーク
    • 主要国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
  • スウェーデン
    • 主要国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
  • ノルウェー
    • 主要国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
• アジア太平洋地域
  • 日本
    • 主要国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
  • 中国
    • 主要国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
  • インド
    • 主要国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
  • 韓国
    • 主要国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
  • タイ
    • 主要国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
  • オーストラリア
    • 主要国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
• ラテンアメリカ
  • ブラジル
    • 主要国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
  • メキシコ
    • 主要国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
  • アルゼンチン
    • 主要国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
• MEA
  • 南アフリカ
    • 主要国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
  • サウジアラビア
    • 主要国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
  • アラブ首長国連邦
    • 主要国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
  • クウェート
    • 主要国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ

第8章 微小残存病変検査市場-競合分析

• 企業/競合の分類（主要なイノベーター、市場のリーダー、新興企業）
• 戦略的枠組み
• 市場参加の分類
• 主要な市場参入企業別最近の動向と影響分析
• 会社のポジション分析
• 代理店一覧
  • 主要顧客
  • 公開会社
  • 非公開会社

第9章 企業プロファイル

• 企業プロファイル
  • EXACT SCIENCES CORPORATION,
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • GRAIL, LLC
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • VERACYTE, INC.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • NATERA, INC.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • GUARDANT HEALTH
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • F. HOFFMANN-LA ROCHE LTD
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • FOUNDATION MEDICINE, INC.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • QIAGEN
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • MDXHEALTH
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • BIO-TECHNE.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Regulatory Framework
• Table 4 Global Minimal Residual Disease Testing Market, By Region, 2018 - 2030 (USD Million)
• Table 5 Global Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
• Table 6 Global Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
• Table 7 Global Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
• Table 8 North America Minimal Residual Disease Testing Market, By Country, 2018 - 2030 (USD Million)
• Table 9 North America Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
• Table 10 North America Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
• Table 11 North America Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
• Table 12 U.S. Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
• Table 13 U.S. Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
• Table 14 U.S. Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
• Table 15 Canada Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
• Table 16 Canada Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
• Table 17 Canada Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
• Table 18 Europe Minimal Residual Disease Testing Market, By Country, 2018 - 2030 (USD Million)
• Table 19 Europe Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
• Table 20 Europe Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
• Table 21 Europe Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
• Table 22 UK Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
• Table 23 UK Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
• Table 24 UK Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
• Table 25 Germany Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
• Table 26 Germany Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
• Table 27 Germany Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
• Table 28 France Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
• Table 29 France Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
• Table 30 France Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
• Table 31 Spain Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
• Table 32 Spain Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
• Table 33 Spain Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
• Table 34 Italy Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
• Table 35 Italy Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
• Table 36 Italy Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
• Table 37 Denmark Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
• Table 38 Denmark Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
• Table 39 Denmark Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
• Table 40 Sweden Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
• Table 41 Sweden Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
• Table 42 Sweden Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
• Table 43 Norway Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
• Table 44 Norway Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
• Table 45 Norway Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
• Table 46 Asia Pacific Minimal Residual Disease Testing Market, By Country, 2018 - 2030 (USD Million)
• Table 47 Asia Pacific Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
• Table 48 Asia Pacific Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
• Table 49 Asia Pacific Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
• Table 50 Japan Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
• Table 51 Japan Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
• Table 52 Japan Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
• Table 53 China Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
• Table 54 China Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
• Table 55 China Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
• Table 56 Australia Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
• Table 57 Australia Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
• Table 58 Australia Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
• Table 59 Thailand Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
• Table 60 Thailand Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
• Table 61 Thailand Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
• Table 62 India Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
• Table 63 India Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
• Table 64 India Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
• Table 65 South Korea Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
• Table 66 South Korea Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
• Table 67 South Korea Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
• Table 68 Latin America Minimal Residual Disease Testing Market, By Country, 2018 - 2030 (USD Million)
• Table 69 Latin America Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
• Table 70 Latin America Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
• Table 71 Latin America Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
• Table 72 Mexico Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
• Table 73 Mexico Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
• Table 74 Mexico Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
• Table 75 Brazil Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
• Table 76 Brazil Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
• Table 77 Brazil Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
• Table 78 Argentina Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
• Table 79 Argentina Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
• Table 80 Argentina Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
• Table 81 MEA Minimal Residual Disease Testing Market, By Country, 2018 - 2030 (USD Million)
• Table 82 MEA Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
• Table 83 MEA Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
• Table 84 MEA Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
• Table 85 South Africa Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
• Table 86 South Africa Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
• Table 87 South Africa Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
• Table 88 Saudi Arabia Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
• Table 89 Saudi Arabia Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
• Table 90 Saudi Arabia Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
• Table 91 UAE Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
• Table 92 UAE Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
• Table 93 UAE Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)
• Table 94 Kuwait Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
• Table 95 Kuwait Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
• Table 96 Kuwait Minimal Residual Disease Testing Market, By End-Use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market Research Process
• Fig. 2 Information Procurement
• Fig. 3 Primary Research Pattern
• Fig. 4 Market Research Approaches
• Fig. 5 Value Chain-Based Sizing & Forecasting
• Fig. 6 Market Formulation & Validation
• Fig. 7 Gastroesophageal Reflux Disease Therapeutics Market Segmentation
• Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
• Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
• Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
• Fig. 11 Penetration & Growth Prospect Mapping
• Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
• Fig. 13 Porter's Five Forces Analysis
• Fig. 14 Market Penetration & Growth Prospect Mapping
• Fig. 15 Minimal residual disease testing market: Technology outlook and key takeaways
• Fig. 16 Minimal residual disease testing market: Technology movement analysis & market share 2022 & 2030
• Fig. 17 Flow cytometry market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 18 Polymerase chain reaction (PCR) market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 19 Next generation sequencing (NGS) market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 20 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 21 Minimal residual disease testing market: Cancer type outlook and key takeaways
• Fig. 22 Minimal residual disease testing market: Cancer type movement analysis & market share 2022 & 2030
• Fig. 23 Haematological malignancy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 24 Solid tumors market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 25 Minimal residual disease testing market: End-Use outlook and key takeaways
• Fig. 26 Minimal residual disease testing market: End-Use movement analysis & market share 2022 & 2030
• Fig. 27 Hospitals and specialty clinics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 28 Diagnostic laboratories market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 29 Academic and research institutes market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 30 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 31 Regional Marketplace: Key Takeaways
• Fig. 32 Regional Outlook, 2022 & 2030
• Fig. 33 Regional Market Dashboard
• Fig. 34 Regional Market Place: Key Takeaways
• Fig. 35 North America, SWOT Analysis
• Fig. 36 Europe, SWOT Analysis
• Fig. 37 Asia Pacific, SWOT Analysis
• Fig. 38 Latin America, SWOT Analysis
• Fig. 39 MEA, SWOT Analysis
• Fig. 40 North America
• Fig. 41 North America Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 42 U.S.
• Fig. 43 U.S. Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 44 Canada
• Fig. 45 Canada Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 46 Europe
• Fig. 47 Europe Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 48 UK
• Fig. 49 UK Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 50 Germany
• Fig. 51 Germany Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 52 France
• Fig. 53 France Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 54 Italy
• Fig. 55 Italy Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 56 Spain
• Fig. 57 Spain Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 58 Denmark
• Fig. 59 Denmark Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 60 Sweden
• Fig. 61 Sweden Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 62 Norway
• Fig. 63 Norway Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 64 Asia Pacific
• Fig. 65 Asia-Pacific Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 66 Japan
• Fig. 67 Japan Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 68 China
• Fig. 69 China Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 70 India
• Fig. 71 India Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 72 Australia
• Fig. 73 Australia Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 74 Thailand
• Fig. 75 Thailand Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 76 South Korea
• Fig. 77 South Korea Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 78 Latin America
• Fig. 79 Latin America Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 80 Brazil
• Fig. 81 Brazil Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 82 Mexico
• Fig. 83 Mexico Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 84 Argentina
• Fig. 85 Argentina Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 86 MEA
• Fig. 87 MEA Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 88 South Africa
• Fig. 89 South Africa Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 90 Saudi Arabia
• Fig. 91 Saudi Arabia Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 92 UAE
• Fig. 93 UAE Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 94 Kuwait
• Fig. 95 Kuwait Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 96 Strategy Mapping

Minimal Residue Disease Testing Market Growth & Trends:

The global minimal residual disease testing market size is expected to reach USD 4.50 billion by 2030, at a CAGR of 11.45% from 2023 to 2030, according to a new report by Grand View Research, Inc. The adoption of MRD testing as a novel diagnostic and prognostic assay facilitates robust moderation of treatment regimes to treat all kinds of hematological malignancies. Measurement of therapeutic outcomes is critical for the successful adoption of a given cancer therapeutic regime.

MRD generates important molecular information to better understand the cancer conditions and ultimately work towards leveraging treatment outcomes. Therefore, MRD testing is increasingly used as an end-point analysis step in numerous clinical trial studies for oncology-based research and also effectively records the variations in outcomes due to individual genetic characteristics. For instance, in November 2020, Adaptive Biotechnologies Corporation, entered into a collaboration with GlaxoSmithKline plc., to use its clonoSEQ assay for the assessment of residual cancer cells after treatment with GSK's hematology therapeutics.

Surgical removal of tumors with other associative therapies does not essentially mean, that the cancerous cells are removed completely. Traces of cancer can remain in the body parts and bloodstream. The diagnosis of such residual cells is crucial for deciding upon the need for further rounds of chemotherapy and radiation. Researchers are devising non-invasive tests to effectively detect MRD. For instance, in February 2022, a blood test from C2i Genomics quantified the residual cancer cells after surgical oncology procedures. The C2inform test also achieved the CE mark clearance and is offered as a 'software-as-a-medical-device' MRD test in Europe.

Cancer therapeutics are effectively moderated to avoid a residue of tumorous cells using the relevant clinical evidence and are also personalized based on specific progression profiles in an individual. Numerous research studies are driving the need for consideration of individual genetic characteristics for effective treatment. For instance, in October 2022, Adaptive Biotechnologies Corporation partnered with Epic for increasing access to MRD monitoring in blood cancers. Moreover, in February 2021, Natera Inc., collaborated with Personalis Inc., to understand the outcomes of personalized cancer care by integrating the NeXT tumor profiling (by Personalis) and the personalized ctDNA platform Signatera's diagnostic products (by Natera, Inc.,) for effectively designing the treatment monitoring regime and assessment of MRD.

Minimal Residue Disease Testing Market Report Highlights:

• The flow cytometry segment held a dominant share in the minimal residual disease testing market in 2022 owing to the high sensitivity and wide applicability of MRD testing

• The hematological malignancy segment is projected to grow at the fastest rate over the forecast period owing to the increasing prevalence of hematological malignancy

• The hospitals and specialty clinics segment is the highest revenue-generating segment in 2022 owing to the availability of advanced diagnostic devices and skilled professionals in hospitals and specialty clinics

• North America dominated the minimal residual disease testing market in 2022, which is attributed to the growing prevalence of hematological malignancies in the region aided by a well-developed reimbursement landscape

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market Segmentation
  • 1.1.1 Estimates And Forecast Timeline
• 1.2 Research Methodology
• 1.3 Information Procurement
  • 1.3.1 Purchased Database
  • 1.3.2 Secondary Sources
  • 1.3.3 Primary Research
  • 1.3.4 Details Of Primary Research
• 1.4 Information Or Data Analysis
  • 1.4.1 Data Analysis Models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
  • 1.6.1 Commodity Flow Analysis
    • 1.6.1.1 Approach 1: Commodity Flow Approach
    • 1.6.1.2 Approach 2: Country-Wise Market Estimation Using Bottom-Up Approach
• 1.7 Global Market: Cagr Calculation
• 1.8 Research Assumptions
• 1.9 List Of Secondary Sources
• 1.10 List Of Primary Sources
• 1.11 Objectives
  • 1.11.1 Objective 1:
  • 1.11.2 Objective 2:
• 1.12 List Of Abbreviations

Chapter 2 Executive Summary

• 2.1 Market Snapshot
• 2.2 Segment Snapshot
• 2.3 Competitive Landscape Snapshot

Chapter 3 Market Variables, Trends & Scope

• 3.1 Minimal Residual Disease Testing Market Lineage Outlook
  • 3.1.1 Parent Market Outlook
    • 3.1.1.1 Cellular Health Screening Market Outlook
    • 3.1.1.2 In Vitro Diagnostics Market Outlook
• 3.2 Penetration And Growth Prospect Mapping
• 3.3 Market Driver Analysis
  • 3.3.1 Increasing Prevalence Of Cancer
  • 3.3.2 Growing Investments In Mrd Testing
  • 3.3.3 Growing Investment For Research
• 3.4 Market Restraint Analysis
  • 3.4.1 High-Cost Associated With Mrd Testing
  • 3.4.2 Complex Regulatory Framework Associated With Mrd Testing
• 3.5 Swot Analysis, By Factor (Political & Legal, Economic, And Technological)
• 3.6 Porter's Five Forces Analysis
• 3.7 Regulatory Framework

Chapter 4 Minimal Residual Disease Testing Market - Segment Analysis, By Technology, 2018 - 2030 (USD Million)

• 4.1 Definition And Scope
• 4.2 Minimal Residual Disease Testing Market: Technology Movement Analysis
  • 4.2.1 Flow Cytometry
    • 4.2.1.1 Flow Cytometry Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.2.2 Polymerase Chain Reaction (Pcr)
    • 4.2.2.1 Polymerase Chain Reaction (Pcr) Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.2.3 Next Generation Sequencing (Ngs)
    • 4.2.3.1 Next Generation Sequencing Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.2.4 Others
    • 4.2.4.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 5 Minimal Residual Disease Testing Market - Segment Analysis, By Cancer Type, 2018 - 2030 (USD Million)

• 5.1 Minimal Residual Disease Testing Market: Cancer Type Movement Analysis
  • 5.1.1 Hematological Malignancy
    • 5.1.1.1 Hematological Malignancy Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.1.2 Solid Tumors
    • 5.1.2.1 Solid Tumors Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6 Minimal Residual Disease Testing Market - Segment Analysis, By Business, 2018 - 2030 (USD Million)

• 6.1 Definition And Scope
• 6.2 Minimal Residual Disease Testing Market: Business Movement Analysis
  • 6.2.1 Hospitals And Speciality Clinics
    • 6.2.1.1 Hospitals And Speciality Clinics Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.2.2 Diagnostic Laboratories
    • 6.2.2.1 Diagnostic Laboratories Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.2.3 Academic And Research Institutes
    • 6.2.3.1 Research Institutes Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.2.4 Others
    • 6.2.4.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 7 Minimal Residual Disease Testing Market - Regional Business Analysis

• 7.1 Definition & Scope
• 7.2 Regional Market Share Analysis, 2022 & 2030
• 7.3 Regional Market Dashboard
• 7.4 Regional Market Snapshot
• 7.5 Swot Analysis, By Factor (Political & Legal, Economic And Technological)
  • 7.5.1 North America
  • 7.5.2 Europe
  • 7.5.3 Asia Pacific
  • 7.5.4 Latin America
  • 7.5.5 MEA
• 7.6 Market Size, & Forecasts, Trend Analysis, 2022 to 2030
• 7.7 North America
  • 7.7.1 North America Market Estimates And Forecast, 2018 - 2030 (USD MILLION)
  • 7.7.2 U.S.
    • 7.7.2.1 U.S. Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
    • 7.7.2.2 Key country Dynamics
    • 7.7.2.3 Regulatory Framework
    • 7.7.2.4 Competitive Scenario
    • 7.7.2.5 Recent Developments
    • 7.7.2.6 Investments Scenario
  • 7.7.3 Canada
    • 7.7.3.1 Canada Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
    • 7.7.3.2 Key country Dynamics
    • 7.7.3.3 Regulatory Framework
    • 7.7.3.4 Competitive Scenario
    • 7.7.3.5 Recent Developments
    • 7.7.3.6 Investments Scenario
• 7.8 Europe
  • 7.8.1 Europe Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
  • 7.8.2 UK
    • 7.8.2.1 UK Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
    • 7.8.2.2 Key country Dynamics
    • 7.8.2.3 Regulatory Framework
    • 7.8.2.4 Competitive Scenario
    • 7.8.2.5 Recent Developments
    • 7.8.2.6 Investments Scenario
  • 7.8.3 Germany
    • 7.8.3.1 Germany Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
    • 7.8.3.2 Key country Dynamics
    • 7.8.3.3 Regulatory Framework
    • 7.8.3.4 Competitive Scenario
    • 7.8.3.5 Recent Developments
    • 7.8.3.6 Investments Scenario
  • 7.8.4 Spain
    • 7.8.4.1 Spain Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
    • 7.8.4.2 Key country Dynamics
    • 7.8.4.3 Regulatory Framework
    • 7.8.4.4 Competitive Scenario
    • 7.8.4.5 Recent Developments
    • 7.8.4.6 Investments Scenario
  • 7.8.5 France
    • 7.8.5.1 France Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
    • 7.8.5.2 Key country Dynamics
    • 7.8.5.3 Regulatory Framework
    • 7.8.5.4 Competitive Scenario
    • 7.8.5.5 Recent Developments
    • 7.8.5.6 Investments Scenario
  • 7.8.6 Italy
    • 7.8.6.1 Italy Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
    • 7.8.6.2 Key country Dynamics
    • 7.8.6.3 Regulatory Framework
    • 7.8.6.4 Competitive Scenario
    • 7.8.6.5 Recent Developments
    • 7.8.6.6 Investments Scenario
  • 7.8.7 Denmark
    • 7.8.7.1 Denmark Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
    • 7.8.7.2 Key country Dynamics
    • 7.8.7.3 Regulatory Framework
    • 7.8.7.4 Competitive Scenario
    • 7.8.7.5 Recent Developments
    • 7.8.7.6 Investments Scenario
  • 7.8.8 Sweden
    • 7.8.8.1 Sweden Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
    • 7.8.8.2 Key country Dynamics
    • 7.8.8.3 Regulatory Framework
    • 7.8.8.4 Competitive Scenario
    • 7.8.8.5 Recent Developments
    • 7.8.8.6 Investments Scenario
  • 7.8.9 Norway
    • 7.8.9.1 Norway Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
    • 7.8.9.2 Key country Dynamics
    • 7.8.9.3 Regulatory Framework
    • 7.8.9.4 Competitive Scenario
    • 7.8.9.5 Recent Developments
    • 7.8.9.6 Investments Scenario
• 7.9 Asia Pacific
  • 7.9.1 Asia-Pacific Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
  • 7.9.2 Japan
    • 7.9.2.1 Japan Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
    • 7.9.2.2 Key country Dynamics
    • 7.9.2.3 Regulatory Framework
    • 7.9.2.4 Competitive Scenario
    • 7.9.2.5 Recent Developments
    • 7.9.2.6 Investments Scenario
  • 7.9.3 China
    • 7.9.3.1 China Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
    • 7.9.3.2 Key country Dynamics
    • 7.9.3.3 Regulatory Framework
    • 7.9.3.4 Competitive Scenario
    • 7.9.3.5 Recent Developments
    • 7.9.3.6 Investments Scenario
  • 7.9.4 India
    • 7.9.4.1 India Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
    • 7.9.4.2 Key country Dynamics
    • 7.9.4.3 Regulatory Framework
    • 7.9.4.4 Competitive Scenario
    • 7.9.4.5 Recent Developments
    • 7.9.4.6 Investments Scenario
  • 7.9.5 South Korea
    • 7.9.5.1 South Korea Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
    • 7.9.5.2 Key country Dynamics
    • 7.9.5.3 Regulatory Framework
    • 7.9.5.4 Competitive Scenario
    • 7.9.5.5 Recent Developments
    • 7.9.5.6 Investments Scenario
  • 7.9.6 Thailand
    • 7.9.6.1 Thailand Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
    • 7.9.6.2 Key country Dynamics
    • 7.9.6.3 Regulatory Framework
    • 7.9.6.4 Competitive Scenario
    • 7.9.6.5 Recent Developments
    • 7.9.6.6 Investments Scenario
  • 7.9.7 Australia
    • 7.9.7.1 Australia Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
    • 7.9.7.2 Key country Dynamics
    • 7.9.7.3 Regulatory Framework
    • 7.9.7.4 Competitive Scenario
    • 7.9.7.5 Recent Developments
    • 7.9.7.6 Investments Scenario
• 7.10 Latin America
  • 7.10.1 Latin America Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
  • 7.10.2 Brazil
    • 7.10.2.1 Brazil Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
    • 7.10.2.2 Key country Dynamics
    • 7.10.2.3 Regulatory Framework
    • 7.10.2.4 Competitive Scenario
    • 7.10.2.5 Recent Developments
    • 7.10.2.6 Investments Scenario
  • 7.10.3 Mexico
    • 7.10.3.1 Mexico Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
    • 7.10.3.2 Key country Dynamics
    • 7.10.3.3 Regulatory Framework
    • 7.10.3.4 Competitive Scenario
    • 7.10.3.5 Recent Developments
    • 7.10.3.6 Investments Scenario
  • 7.10.4 Argentina
    • 7.10.4.1 Argentina Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
    • 7.10.4.2 Key country Dynamics
    • 7.10.4.3 Regulatory Framework
    • 7.10.4.4 Competitive Scenario
    • 7.10.4.5 Recent Developments
    • 7.10.4.6 Investments Scenario
• 7.11 MEA
  • 7.11.1 MEA Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
  • 7.11.2 South Africa
    • 7.11.2.1 South Africa Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
    • 7.11.2.2 Key country Dynamics
    • 7.11.2.3 Regulatory Framework
    • 7.11.2.4 Competitive Scenario
    • 7.11.2.5 Recent Developments
    • 7.11.2.6 Investments Scenario
  • 7.11.3 Saudi Arabia
    • 7.11.3.1 Saudi Arabia Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
    • 7.11.3.2 Key country Dynamics
    • 7.11.3.3 Regulatory Framework
    • 7.11.3.4 Competitive Scenario
    • 7.11.3.5 Recent Developments
    • 7.11.3.6 Investments Scenario
  • 7.11.4 UAE
    • 7.11.4.1 UAE Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
    • 7.11.4.2 Key country Dynamics
    • 7.11.4.3 Regulatory Framework
    • 7.11.4.4 Competitive Scenario
    • 7.11.4.5 Recent Developments
    • 7.11.4.6 Investments Scenario
  • 7.11.5 Kuwait
    • 7.11.5.1 Kuwait Minimal Residual Disease Testing Market, 2018 - 2030 (USD Million)
    • 7.11.5.2 Key country Dynamics
    • 7.11.5.3 Regulatory Framework
    • 7.11.5.4 Competitive Scenario
    • 7.11.5.5 Recent Developments
    • 7.11.5.6 Investments Scenario

Chapter 8 Minimal Residual Disease Testing Market - Competitive Analysis

• 8.1 Company/Competition Categorization (Key Innovators, Market leaders, Emerging Players)
• 8.2 Strategy Framework
• 8.3 Market Participation Categorization
• 8.4 Recent Developments & Impact Analysis, by Key Market Participants
• 8.5 Company Position Analysis
• 8.6 List of Distributors
  • 8.6.1 Key Customers
  • 8.6.2 Public Companies
  • 8.6.3 Private Companies

Chapter 9 Company Profiles

• 9.1 Company Profiles
  • 9.1.1 EXACT SCIENCES CORPORATION,
    • 9.1.1.1 Company Overview
    • 9.1.1.2 Financial Performance
    • 9.1.1.3 Product Benchmarking
    • 9.1.1.4 Strategic Initiatives
  • 9.1.2 GRAIL, LLC
    • 9.1.2.1 Company Overview
    • 9.1.2.2 Financial performance
    • 9.1.2.3 Product Benchmarking
    • 9.1.2.4 Strategic Initiatives
  • 9.1.3 VERACYTE, INC.
    • 9.1.3.1 Company Overview
    • 9.1.3.2 Financial performance
    • 9.1.3.3 Product Benchmarking
    • 9.1.3.4 Strategic Initiatives
  • 9.1.4 NATERA, INC.
    • 9.1.4.1 Company Overview
    • 9.1.4.2 Financial performance
    • 9.1.4.3 Product Benchmarking
    • 9.1.4.4 Strategic Initiatives
  • 9.1.5 GUARDANT HEALTH
    • 9.1.5.1 Company Overview
    • 9.1.5.2 Financial performance
    • 9.1.5.3 Product Benchmarking
    • 9.1.5.4 Strategic Initiatives
  • 9.1.6 F. HOFFMANN-LA ROCHE LTD
    • 9.1.6.1 Company Overview
    • 9.1.6.2 Financial performance
    • 9.1.6.3 Product Benchmarking
    • 9.1.6.4 Strategic Initiatives
  • 9.1.7 FOUNDATION MEDICINE, INC.
    • 9.1.7.1 Company Overview
    • 9.1.7.2 Financial performance
    • 9.1.7.3 Product Benchmarking
    • 9.1.7.4 Strategic Initiatives
  • 9.1.8 QIAGEN
    • 9.1.8.1 Company Overview
    • 9.1.8.2 Financial performance
    • 9.1.8.3 Product Benchmarking
    • 9.1.8.4 Strategic Initiatives
  • 9.1.9 MDXHEALTH
    • 9.1.9.1 Company Overview
    • 9.1.9.2 Financial performance
    • 9.1.9.3 Product Benchmarking
    • 9.1.9.4 Strategic Initiatives
  • 9.1.10 BIO-TECHNE.
    • 9.1.10.1 Company Overview
    • 9.1.10.2 Financial performance
    • 9.1.10.3 Product Benchmarking
    • 9.1.10.4 Strategic Initiatives